Chonnam Med J.  2010 Apr;46(1):1-6. 10.4068/cmj.2010.46.1.1.

The Clinical Impact of the Dendritic Cell-based Cancer Vaccine: the Role in the Inflammatory Tumor Micro-environment

• Lee H

• KMID: 2172250
• DOI: http://doi.org/10.4068/cmj.2010.46.1.1

Abstract

As a novel therapeutic module, the dendritic cell (DC) based cancer vaccine has been recognized with great hope in eliminating cancers, including minimal residual cells, without harming normal tissue. A key factor in initiating and operating the immune system against foreign bodies including tumor cells, the DC has been regarded as the next possible breakthrough in new cancer therapy. However, the results of more than 15 years of clinical studies with DC vaccine revealed the difficulties fulfilling this expectation. Evidence has disclosed that the DC activation required for proper tumor-specific effector CD4+ and CD8+ T cell stimulation is inhibited in the micro-environment of cancer. Studies have further reported that DC phenotypes in cancer tissue and draining lymph nodes are mostly immature, which results in regulatory immune responses. Also, the existence of myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs) adversely affect both DC function and immune suppression in the cancer-environment. In this review, the impact of an inflammatory micro-environment induced by cancer on the effect of DC-based cancer immunotherapy and the possibility of a clinical efficacy improvement are discussed.

Keyword

Cancer immunotherapy; DC-based cancer vaccine; tumor micro-environment

MeSH Terms

Dendritic Cells
Foreign Bodies
Immune System
Immunotherapy
Lymph Nodes
Macrophages
Phenotype

Reference

1. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996. 2:52–58.

2. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998. 4:328–332.

3. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005. 5:296–306.

4. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004. 10:475–480.

5. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004. 4:401–411.

6. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007. 449:419–426.

7. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol. 2005. 17:163–169.

8. Pardoll DM. Cancer vaccines. Nat Med. 1998. 4:5 Suppl. 525–531.

9. Parmiani G, Pilla L, Castelli C, Rivoltini L. Vaccination of patients with solid tumours. Ann Oncol. 2003. 14:817–824.

10. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol. 1996. 24:859–862.

11. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer. 2001. 94:459–473.

12. Palucka AK, Ueno H, Fay J, Banchereau J. Dendritic cells: a critical player in cancer therapy? J Immunother. 2008. 31:793–805.

13. Melief C. Cancer immunotherapy by dendritic cells. Immunity. 2008. 29:372–383.

14. Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol. 2009. 5:379–390.

15. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol. 2008. 20:228–233.

16. Koebel C, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007. 450:903–907.

17. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006. 6:836–848.

18. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008. 453:410–414.

19. Hamzah J, Nelson D, et al. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest. 2008. 118:1691–1699.

20. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009. 58:1–14.

21. Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A. Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev. 2008. 60:173–183.

22. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007. 117:1195–1203.

23. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991. 9:271–296.

24. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998. 392:245–252.

25. Gabrilovich D. Mechanisms and functional significance of tumour induced dendritic-cell defects. Nat Rev Immunol. 2004. 4:941–952.

26. Schuurhuis D, Fu N, Ossendorp F, Melief CJ. Ins and outs of dendritic cells. Int Arch Allergy Immunol. 2006. 140:53–72.

27. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 2008. 15:39–50.

28. Boonman ZF, van Mierlo GJ, Fransen MF, de Keizer RJ, Jager MJ, Melief CJ, et al. Maintenance of immune tolerance depends on normal tissue homeostasis. J Immunol. 2005. 175:4247–4254.

29. van Mierlo G, Boonman Z, Dumortier HM, den Boer AT, Fransen MF, Nouta J, et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol. 2004. 173:6753–6759.

30. Yang L, Carbone DP. Tumor host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 2004. 92:13–27.

31. Pinzon-Charry A, Maxwell T, López JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol. 2005. 83:451–461.

32. Uchida K, Schneider S, Yochim JM, Kuramochi H, Hayashi K, Takasaki K, et al. Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res. 2005. 11:3363–3368.

33. Williams C, Shattuck-Brandt RL, DuBois RN. The role of COX-2 in intestinal cancer. Ann N Y Acad Sci. 1999. 889:72–83.

34. Inaba T, Sano H, Kawahito Y, Hla T, Akita K, Toda M, et al. Induction of cyclooxygenase-2 in monocyte /macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci USA. 2003. 100:2736–2741.

35. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004. 10:8465–8471.

36. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001. 166:678–689.

37. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000. 6:1755–1766.

38. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001. 166:5398–5306.

39. Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer. 1997. 74:69–74.

40. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med. 1999. 190:1417–1426.

41. Toriyama K, Wen DR, Paul E, Cochran AJ. Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol. 1993. 100:S269–S273.

42. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res. 1998. 4:585–593.

43. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001. 7:1339–1346.

44. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer. 2003. 89:1463–1472.

45. Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol. 2004. 172:464–474.

46. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004. 10:48–54.

47. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005. 11:1314–1321.

48. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med. 2005. 202:919–929.

49. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003. 63:1270–1279.

50. van Kester MS, Out-Luiting JJ, von dem Borne PA, Willemze R, Tensen CP, Vermeer MH. Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells. J Invest Dermatol. 2008. 128:1691–1695.

51. Mantovani A, Pierotti MA. Cancer and inflammation: a complex relationship. Cancer Lett. 2008. 267:180–181.

52. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007. 117:1155–1166.

53. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumorinduced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008. 222:162–179.

54. Borrello MG, Degl'innocenti D, Pierotti M. Inflammation and cancer: the oncogene-driven connection. Cancer Lett. 2008. 267:262–270.

55. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008. 267:271–285.

56. Ostrand-Rosenberg S, Sinha P. Myeoid-Derived suppressor cells: linking inflammation and cancer. J Immunol. 2009. 182:4499–4506.

57. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002. 420:860–867.

58. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008. 8:579–591.

59. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008. 13:23–35.

60. Marx J. Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science. 2008. 319:154–156.

61. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukocyte Biol. 2008. 83:1136–1144.

62. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006. 116:2777–2790.

63. Rossner S, Voigtlander C, Wiethe C, Hänig J, Seifarth C, Lutz MB. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol. 2005. 35:3533–3544.

64. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006. 66:1123–1131.

65. Yang R, Cai Z, Zhang Y, Yutzy WH 4th, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+ CD11b+ myeloid cells. Cancer Res. 2006. 66:6807–6815.

66. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumorbearing mice. J Immunol. 2008. 181:5791–5802.

67. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008. 111:5457–5466.

68. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004. 172:989–999.

69. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, et al. IL-4-induced arginase 1 suppresses allo-reactive T cells in tumor-bearing mice. J Immunol. 2003. 170:270–278.

70. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007. 67:4507–4513.

71. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003. 24:302–306.

72. Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukocyte Biol. 2003. 74:186–196.

73. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007. 25:2546–2553.

74. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008. 135:234–243.

75. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005. 65:3044–3048.

76. Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2008. 57:1493–1504.

77. Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1 +/Gr-1+ cells. J Immunol. 1998. 161:5313–5320.

78. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000. 96:3838–3846.

79. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001. 166:5398–5406.

80. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol. 2002. 168:689–695.

81. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, et al. A non-classical non-Valpha 14Jalpha 18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med. 2005. 202:1627–1633.

82. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother. 2009. 58:317–324.